Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 684

1.

Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic.

Wei DY, Moreno-Ajona D, Renton T, Goadsby PJ.

J Headache Pain. 2019 Jun 11;20(1):69. doi: 10.1186/s10194-019-1019-7.

2.

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD.

Cephalalgia. 2019 May 30:333102419854082. doi: 10.1177/0333102419854082. [Epub ahead of print]

PMID:
31146544
3.

James W. Lance MD.

Goadsby PJ.

Headache. 2019 Jun;59(6):825-827. doi: 10.1111/head.13552. No abstract available.

PMID:
31144299
4.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C.

Brain. 2019 May 27. pii: awz134. doi: 10.1093/brain/awz134. [Epub ahead of print]

PMID:
31132795
5.

Marco Polo of Australian neurology.

Kiernan MC, Goadsby PJ, Burke D.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):627-628. doi: 10.1136/jnnp-2019-320989. Epub 2019 May 2. No abstract available.

PMID:
31048340
6.

N-Methyl-d-aspartate receptor open-channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats.

Hoffmann J, Storer RJ, Park JW, Goadsby PJ.

Eur J Neurosci. 2019 Apr 22. doi: 10.1111/ejn.14423. [Epub ahead of print]

PMID:
31009120
7.

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.

Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q, Skljarevski V, Aurora SK.

J Neurol Neurosurg Psychiatry. 2019 Apr 19. pii: jnnp-2018-320242. doi: 10.1136/jnnp-2018-320242. [Epub ahead of print]

8.

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.

Cephalalgia. 2019 Jun;39(7):817-826. doi: 10.1177/0333102419835459. Epub 2019 Apr 13.

PMID:
30982348
9.

The discovery and development of inhaled therapeutics for migraine.

Vandenbussche N, Goadsby PJ.

Expert Opin Drug Discov. 2019 Jun;14(6):591-599. doi: 10.1080/17460441.2019.1598373. Epub 2019 Mar 29.

PMID:
30924698
10.

Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences.

Matza LS, Deger KA, Vo P, Maniyar F, Goadsby PJ.

Qual Life Res. 2019 Mar 28. doi: 10.1007/s11136-019-02163-3. [Epub ahead of print]

PMID:
30924071
11.

Dr James Lance, Professor of Neurology in Sydney, Australia, died on 20 February 2019, age 92.

Edvinsson L, Evers S, Goadsby PJ.

Cephalalgia. 2019 Apr;39(5):681-682. doi: 10.1177/0333102419840639. Epub 2019 Mar 21. No abstract available.

PMID:
30897943
12.

Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study.

Filippi M, Messina R, Goadsby PJ, Rocca MA.

Neurology. 2019 Mar 19;92(12):587-588. doi: 10.1212/WNL.0000000000007132. No abstract available.

PMID:
30886079
13.

Discovery of CGRP in relation to migraine.

Edvinsson L, Goadsby PJ.

Cephalalgia. 2019 Mar;39(3):331-332. doi: 10.1177/0333102418779544. No abstract available.

PMID:
30827155
14.

Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2019 May;39(6):687-710. doi: 10.1177/0333102419828967. Epub 2019 Feb 26.

15.

Teaching NeuroImages: Greater occipital nerve injection: A cautionary tale.

Wei DY, Connor S, Goadsby PJ.

Neurology. 2019 Feb 12;92(7):e746-e747. doi: 10.1212/WNL.0000000000006929. No abstract available.

PMID:
30745452
16.

Lorcaserin Safety in Overweight or Obese Patients.

Vandenbussche N, Goadsby PJ.

N Engl J Med. 2019 Jan 3;380(1):99. doi: 10.1056/NEJMc1813971. No abstract available.

PMID:
30601744
17.

Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.

Akerman S, Karsan N, Bose P, Hoffmann JR, Holland PR, Romero-Reyes M, Goadsby PJ.

Brain. 2019 Jan 1;142(1):103-119. doi: 10.1093/brain/awy313.

18.

Cortical abnormalities in episodic migraine: A multi-center 3T MRI study.

Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, Amin FM, Seifert CL, Mallar Chakravarty M, Müller J, Sprenger T.

Cephalalgia. 2019 Apr;39(5):665-673. doi: 10.1177/0333102418795163. Epub 2018 Dec 10.

PMID:
30525946
19.

Biological insights from the premonitory symptoms of migraine.

Karsan N, Goadsby PJ.

Nat Rev Neurol. 2018 Dec;14(12):699-710. doi: 10.1038/s41582-018-0098-4. Review.

PMID:
30448858
20.

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK.

Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.

21.

Divergent influences of the locus coeruleus on migraine pathophysiology.

Vila-Pueyo M, Strother LC, Kefel M, Goadsby PJ, Holland PR.

Pain. 2019 Feb;160(2):385-394. doi: 10.1097/j.pain.0000000000001421.

22.

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.

Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22.

PMID:
30360965
23.

Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA.

Headache. 2018 Nov;58(10):1658-1669. doi: 10.1111/head.13414. Epub 2018 Oct 15. No abstract available.

PMID:
30324723
24.

Prolonged migraine aura: new insights from a prospective diary-aided study.

Viana M, Sances G, Linde M, Nappi G, Khaliq F, Goadsby PJ, Tassorelli C.

J Headache Pain. 2018 Aug 31;19(1):77. doi: 10.1186/s10194-018-0910-y.

25.

The Migraine Postdrome.

Bose P, Karsan N, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):1023-1031. doi: 10.1212/CON.0000000000000626.

PMID:
30074547
26.

The Migraine Premonitory Phase.

Karsan N, Bose P, Goadsby PJ.

Continuum (Minneap Minn). 2018 Aug;24(4, Headache):996-1008. doi: 10.1212/CON.0000000000000624.

PMID:
30074545
27.

Identifying Natural Subgroups of Migraine Based on Comorbidity and Concomitant Condition Profiles: Results of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.

Lipton RB, Fanning KM, Buse DC, Martin VT, Reed ML, Manack Adams A, Goadsby PJ.

Headache. 2018 Jul;58(7):933-947. doi: 10.1111/head.13342. Epub 2018 Jul 19.

PMID:
30024028
28.

Cluster Headache and Calcitonin Gene-Related Peptide-More on Quantum Therapeutics in Headache Medicine.

Gelfand AA, Goadsby PJ.

JAMA Neurol. 2018 Oct 1;75(10):1179-1180. doi: 10.1001/jamaneurol.2018.1428. No abstract available.

PMID:
29987331
29.

Recent advances in headache neuroimaging.

Messina R, Filippi M, Goadsby PJ.

Curr Opin Neurol. 2018 Aug;31(4):379-385. doi: 10.1097/WCO.0000000000000573. Review.

PMID:
29952833
30.

Gray matter volume modifications in migraine: A cross-sectional and longitudinal study.

Messina R, Rocca MA, Colombo B, Pagani E, Falini A, Goadsby PJ, Filippi M.

Neurology. 2018 Jul 17;91(3):e280-e292. doi: 10.1212/WNL.0000000000005819. Epub 2018 Jun 20.

PMID:
29925551
31.

Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium.

Lipton RB, Goadsby PJ.

Neurology. 2018 Jul 24;91(4):167. doi: 10.1212/WNL.0000000000005870. Epub 2018 Jun 15. No abstract available.

PMID:
29907607
32.

Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family.

Marques P, Barry S, Ronaldson A, Ogilvie A, Storr HL, Goadsby PJ, Powell M, Dang MN, Chahal HS, Evanson J, Kumar AV, Grieve J, Korbonits M.

Int J Endocrinol. 2018 Apr 4;2018:8581626. doi: 10.1155/2018/8581626. eCollection 2018.

33.

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

JAMA. 2018 May 15;319(19):1999-2008. doi: 10.1001/jama.2018.4853.

PMID:
29800211
34.

Overview of Trigeminal Autonomic Cephalalgias: Nosologic Evolution, Diagnosis, and Management.

Wei DY, Yuan Ong JJ, Goadsby PJ.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S39-S44. doi: 10.4103/aian.AIAN_348_17. Review.

35.

Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis.

Wei DY, Yuan Ong JJ, Goadsby PJ.

Ann Indian Acad Neurol. 2018 Apr;21(Suppl 1):S3-S8. doi: 10.4103/aian.AIAN_349_17. Review.

36.

Migraine Therapy: Current Approaches and New Horizons.

Goadsby PJ, Holland PR.

Neurotherapeutics. 2018 Apr;15(2):271-273. doi: 10.1007/s13311-018-0626-3. No abstract available.

37.

CGRP - a target for acute therapy in migraine: Clinical data.

Messina R, Goadsby PJ.

Cephalalgia. 2019 Mar;39(3):420-427. doi: 10.1177/0333102418768095. Epub 2018 Apr 4.

PMID:
29616830
38.

Migraine is common in patients with sarcoidosis.

Gelfand JM, Gelfand AA, Goadsby PJ, Benn BS, Koth LL.

Cephalalgia. 2018 Dec;38(14):2079-2082. doi: 10.1177/0333102418768037. Epub 2018 Mar 26.

PMID:
29580067
39.

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Holland PR, Goadsby PJ.

Neurotherapeutics. 2018 Apr;15(2):304-312. doi: 10.1007/s13311-018-0617-4. Review.

40.

Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Open-Label Study.

Irwin SL, Qubty W, Allen IE, Patniyot I, Goadsby PJ, Gelfand AA.

Headache. 2018 May;58(5):724-731. doi: 10.1111/head.13284. Epub 2018 Mar 12.

PMID:
29528485
41.

Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK.

Karsan N, Palethorpe D, Rattanawong W, Marin JC, Bhola R, Goadsby PJ.

Eur J Neurol. 2018 Jun;25(6):811-817. doi: 10.1111/ene.13621. Epub 2018 Apr 11.

PMID:
29512871
42.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 May;38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4.

43.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
44.

Preventive Therapies for Chronic Migraine.

Goadsby PJ, Picard H, Mikol DD.

N Engl J Med. 2018 Feb 22;378(8):774-5. doi: 10.1056/NEJMc1716990. No abstract available.

PMID:
29469553
45.

Case Report of the Safety Assessment of Transcranial Magnetic Stimulation Use in a Patient With Cardiac Pacemaker: To Pulse or Not to Pulse?

Wei DY, Greenwood FS, Murgatroyd FD, Goadsby PJ.

Headache. 2018 Feb;58(2):295-297. doi: 10.1111/head.13258.

PMID:
29411366
46.

Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Ong JJY, Wei DY, Goadsby PJ.

Drugs. 2018 Mar;78(4):411-437. doi: 10.1007/s40265-018-0865-y. Review.

PMID:
29396834
47.
48.

Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta.

Özge A, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalın OÖ, Faedda N, Lipton RB, Rapoport A, Guidetti V.

J Headache Pain. 2017 Nov 29;18(1):113. doi: 10.1186/s10194-017-0819-x.

49.

Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents.

Özge A, Faedda N, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalın OÖ, Lipton RB, Rapoport A, Guidetti V.

J Headache Pain. 2017 Nov 23;18(1):109. doi: 10.1186/s10194-017-0818-y. Review.

50.

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.

Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW.

JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859. Erratum in: JAMA Neurol. 2018 Feb 1;75(2):260.

Supplemental Content

Loading ...
Support Center